Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million

Reuters2026/08/03 11:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Twist Bioscience posted fiscal 3Q revenue of $118.4 million, up 23% year over year, beating guidance of $114 million-$115 million.
Gross margin rose to 52.8%, up about 120 basis points sequentially from fiscal 2Q.
Adjusted EBITDA loss narrowed to $11.3 million as the company said it is on track for breakeven in fiscal 4Q.
DNA synthesis and protein solutions revenue climbed 39% year over year to $56.6 million, with about 369,000 genes shipped.
NGS applications revenue increased 12% year over year to $61.8 million, with growth led by diagnostic customers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million

You may also like

Crypto prices